文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

用创新应对青少年和青年盆腔炎健康差异:TECH-PN试验设计

Using Innovation to Address Adolescent and Young Adult Health Disparities in Pelvic Inflammatory Disease: Design of the Technology Enhanced Community Health Precision Nursing (TECH-PN) Trial.
PubMed 文献 · J Infect Dis · 2021-01-01

TECH-PN随机对照试验针对城市13–25岁女性急性轻中度盆腔炎患者,评估精准护理干预的可行性与可接受性。前13个月75.2%患者符合条件,76.1%入组,94%完成干预,14/30/90天随访完成率分别为96%、91%、89%。基线生殖支原体感染率45%、沙眼衣原体31%。

要点

  • 城市青少年和青年女性盆腔炎患者中生殖支原体感染率最高(45%),其次为沙眼衣原体(31%)。
  • 精准护理干预(基于 interim STI 和大环内酯耐药检测)在13个月内显示高入组率、干预完成率和随访保留率。
  • 该设计支持在盆腔炎患者中开展基于检测的精准护理以应对年龄和种族健康差异。

核心结论

  • TECH-PN干预在城市青少年和青年盆腔炎患者中具有可行性和可接受性。

研究设计与样本

  • 随机对照试验,纳入13–25岁出生时指定为女性、急性轻中度盆腔炎的城市青少年和青年,提供基线和随访访谈及阴道标本检测。
  • 所有参与者接受药物治疗和短信支持,随机分为对照组(1次社区护理访视)和干预组(基于 interim STI 和大环内酯耐药检测的无限精准护理服务)。

主要发现

  • 前13个月75.2%患者符合条件,76.1%符合条件的患者入组。
  • 94%参与者完成干预,14天、30天和90天随访完成率分别为96%、91%和89%。
  • 基线感染率最高为生殖支原体(45%),其次为沙眼衣原体(31%)。

临床怎么用

  • 在青少年和青年盆腔炎管理中可考虑结合 interim STI 和大环内酯耐药检测指导精准护理。
  • 短信支持和社区护理访视可能有助于提高治疗完成率和随访保留。

局限性

  • 本文报告的是13个月初步可行性和可接受性结果,非疗效终点的最终分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New approaches to pelvic inflammatory disease (PID) care among adolescents and young adults (AYAs) that optimize self-care and personalize treatment are warranted to address age and racial-ethnic PID-related health disparities. Here we describe the 13-month preliminary feasibility and acceptability outcomes of recruitment, retention, and intervention delivery for Technology Enhanced Community Health Precision Nursing (TECH-PN) randomized controlled trial. Urban AYAs 13-25 years assigned female sex at birth with acute mild-moderate PID provided baseline and follow-up interview data and vaginal specimens for sexually transmitted infection (STI), cytokine, and microbiota assessment. All participants received medications and text-messaging support. Participants were block randomized to either control or intervention. Control participants received 1 community nursing visit with self-management for interim care per national guidelines. Intervention participants received unlimited precision care services driven by interim STI and macrolide resistance testing results by an advanced practice provider. In the first 13 months, 75.2% patients were eligible, and 76.1% of eligible patients enrolled. Of the participants, 94% completed the intervention and 96%, 91%, and 89%, respectively, completed their 14-, 30-, and 90-day visits. Baseline laboratory results revealed infection rates that were highest for Mycoplasma genitalium (45%) followed by Chlamydia trachomatis (31%). Preliminary enrollment, STI, intervention delivery, and retention data demonstrate the feasibility and acceptability of the TECH-PN intervention and support rationale for precision care for PID among urban AYAs. ClinicalTrials.gov Identifier. NCT03828994.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Trent M, Perin J, Rowell J, et al. Using Innovation to Address Adolescent and Young Adult Health Disparities in Pelvic Inflammatory Disease: Design of the Technology Enhanced Community Health Precision Nursing (TECH-PN) Trial. J Infect Dis. 2021. PMID: 34396402. doi:10.1093/infdis/jiab157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。